Mateus Dornelles Severo1, Thais Stürmer Andrade1, Vicente Correa Junior2, Alexandre Antonio Naujorks3, Miguel Gus2, Beatriz D Schaan4,5. 1. Programa de Pós-Graduação em Endocrinologia, Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Rua Ramiro Barcelos, 2400, 2° andar, Porto Alegre, RS, 90035-003, Brazil. 2. Programa de Pós-Graduação em Cardiologia, Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Rua Ramiro Barcelos, 2400, 2° andar, Porto Alegre, RS, 90035-003, Brazil. 3. Universidade Federal de Santa Maria, Avenida Roraima, 1000, Santa Maria, RS, 97105-900, Brazil. 4. Programa de Pós-Graduação em Endocrinologia, Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Rua Ramiro Barcelos, 2400, 2° andar, Porto Alegre, RS, 90035-003, Brazil. bschaan@hcpa.edu.br. 5. Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, 2° andar, Porto Alegre, RS, 90035-903, Brazil. bschaan@hcpa.edu.br.
Abstract
INTRODUCTION: Non-randomized trials suggest that metformin may reduce TSH levels through unknown mechanisms. OBJECTIVE: To evaluate whether metformin can reduce TSH levels in subjects with subclinical hypothyroidism. PATIENTS AND METHODS: This is a randomized, double-blind, placebo controlled clinical trial with 3 months duration that enrolled 48 individuals, between 18 and 65 years, with subclinical hypothyroidism. The patients were randomized to the use of metformin 850 mg or placebo twice a day for 3 months. The primary outcome was the absolute decrease in TSH levels. Secondary outcomes were changes in the clinical and laboratory assessment, as well as in blood pressure assessed by ambulatory blood pressure monitoring. RESULTS: After 3 months, 93.75% of participants completed the follow-up. The post treatment value of TSH in the metformin and placebo groups were 6.48 ± 3.11 and 7.02 ± 3.28 mIU/L, respectively (p = 0.57). Patients who achieved status of euthyroidism in the metformin and placebo groups were 21.7 and 18.2%, respectively (p = 0.76). There was no significant reduction of TSH within the groups [delta for TSH of 0.63 ± 0.56 (p = 0.28) and 0.54 ± 0.60 mIU/L (p = 0.38), in metformin and placebo groups, respectively]. There was a small increase in HDL cholesterol (1.62 ± 0.45 vs. 1.34 ± 0.39 mmol/L, p = 0.03) favoring the metformin group. CONCLUSION: Since the sample size was small, the study was inconclusive and the results should be considered preliminary data of a study that needs to enroll 1626 patients to show a 0.5 mIU/L difference in TSH between the groups, with 90% power.
RCT Entities:
INTRODUCTION: Non-randomized trials suggest that metformin may reduce TSH levels through unknown mechanisms. OBJECTIVE: To evaluate whether metformin can reduce TSH levels in subjects with subclinical hypothyroidism. PATIENTS AND METHODS: This is a randomized, double-blind, placebo controlled clinical trial with 3 months duration that enrolled 48 individuals, between 18 and 65 years, with subclinical hypothyroidism. The patients were randomized to the use of metformin 850 mg or placebo twice a day for 3 months. The primary outcome was the absolute decrease in TSH levels. Secondary outcomes were changes in the clinical and laboratory assessment, as well as in blood pressure assessed by ambulatory blood pressure monitoring. RESULTS: After 3 months, 93.75% of participants completed the follow-up. The post treatment value of TSH in the metformin and placebo groups were 6.48 ± 3.11 and 7.02 ± 3.28 mIU/L, respectively (p = 0.57). Patients who achieved status of euthyroidism in the metformin and placebo groups were 21.7 and 18.2%, respectively (p = 0.76). There was no significant reduction of TSH within the groups [delta for TSH of 0.63 ± 0.56 (p = 0.28) and 0.54 ± 0.60 mIU/L (p = 0.38), in metformin and placebo groups, respectively]. There was a small increase in HDL cholesterol (1.62 ± 0.45 vs. 1.34 ± 0.39 mmol/L, p = 0.03) favoring the metformin group. CONCLUSION: Since the sample size was small, the study was inconclusive and the results should be considered preliminary data of a study that needs to enroll 1626 patients to show a 0.5 mIU/L difference in TSH between the groups, with 90% power.
Authors: Nicolas Rodondi; Wendy P J den Elzen; Douglas C Bauer; Anne R Cappola; Salman Razvi; John P Walsh; Bjørn O Asvold; Giorgio Iervasi; Misa Imaizumi; Tinh-Hai Collet; Alexandra Bremner; Patrick Maisonneuve; José A Sgarbi; Kay-Tee Khaw; Mark P J Vanderpump; Anne B Newman; Jacques Cornuz; Jayne A Franklyn; Rudi G J Westendorp; Eric Vittinghoff; Jacobijn Gussekloo Journal: JAMA Date: 2010-09-22 Impact factor: 56.272
Authors: Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Elizabeth Selvin; Shari Bolen; Hsin-Chieh Yeh; Crystal Wiley; Lisa M Wilson; Spyridon S Marinopoulos; Leonard Feldman; Jason Vassy; Renee Wilson; Eric B Bass; Frederick L Brancati Journal: Arch Intern Med Date: 2008-10-27
Authors: Carlo Cappelli; Mario Rotondi; Ilenia Pirola; Barbara Agosti; Elena Gandossi; Umberto Valentini; Elvira De Martino; Antonio Cimino; Luca Chiovato; Enrico Agabiti-Rosei; Maurizio Castellano Journal: Diabetes Care Date: 2009-06-05 Impact factor: 19.112
Authors: R Palui; J Sahoo; S Kamalanathan; S S Kar; K Sridharan; H Durgia; H Raj; M Patil Journal: J Endocrinol Invest Date: 2019-05-24 Impact factor: 4.256